Department of Hematology, Nippon Medical School.
Department of Microbiology and Immunology, Nippon Medical School.
J Nippon Med Sch. 2022 Jun 28;89(3):301-308. doi: 10.1272/jnms.JNMS.2022_89-305. Epub 2021 Nov 26.
Primary thyroid lymphoma (PTL) is a rare disease frequently arising against a background of autoimmune thyroiditis. It has recently been reported that the inactivation of the NF-κB negative regulator A20 by deletion and/or mutation could be involved in the pathogenesis of subsets of B-cell lymphomas. This study investigated the clinicopathologic characteristics and A20 mutation in patients with PTL.
We analyzed the characteristics of 45 PTL patients (14 men and 31 women), with a median age of 71 (range, 35-90) years. A20 mutations were analyzed in DNA extracted from 20 samples consisting of 19 tumor tissue samples and 1 sample from Hashimoto's thyroiditis.
Thirty-five patients (82%) had a history of Hashimoto's thyroiditis, and 29 (64%) had diffuse large B-cell lymphoma (DLBCL) and presented with larger tumors including bulky mass, elevated soluble interleukin-2 receptor levels, and a longer history of Hashimoto's thyroiditis than that of patients with mucosa-associated lymphoid tissue (MALT) lymphoma (n=16). A20 mutations were identified in 3 of 19 PTL patients (16%), in 2 of the 10 (20%) with DLBCL and in 1 of the 9 (11%) with MALT lymphoma. Interestingly, all patients with A20 mutations had Hashimoto's thyroiditis. Furthermore, they had a common missense variant in exon 3 (rs2230926 380T>G; F127C), which reduces the ability of A20 to inhibit NF-κB signaling.
Our study suggests that the histological features of PTL affect clinical outcomes and that A20 mutations are related to PTL pathogenesis in some patients with Hashimoto's thyroiditis.
原发性甲状腺淋巴瘤(PTL)是一种罕见疾病,常发生在自身免疫性甲状腺炎的背景下。最近有报道称,NF-κB 负调节因子 A20 的缺失和/或突变失活可能与部分 B 细胞淋巴瘤的发病机制有关。本研究调查了 PTL 患者的临床病理特征和 A20 突变情况。
我们分析了 45 例 PTL 患者(14 例男性,31 例女性)的特征,中位年龄为 71 岁(范围,35-90 岁)。从 19 例肿瘤组织样本和 1 例桥本甲状腺炎样本中提取 DNA,分析 A20 突变。
35 例(82%)患者有桥本甲状腺炎病史,29 例(64%)患者为弥漫性大 B 细胞淋巴瘤(DLBCL),且肿瘤较大,包括肿块较大、可溶性白细胞介素-2 受体水平升高、桥本甲状腺炎病史较长,而黏膜相关淋巴组织(MALT)淋巴瘤(n=16)患者的肿瘤较小。在 19 例 PTL 患者中发现 A20 突变 3 例(16%),在 10 例 DLBCL 中发现 2 例(20%),在 9 例 MALT 淋巴瘤中发现 1 例(11%)。有趣的是,所有 A20 突变患者均有桥本甲状腺炎。此外,他们在exon 3 都有一个常见的错义变异(rs2230926 380T>G;F127C),这降低了 A20 抑制 NF-κB 信号的能力。
本研究表明,PTL 的组织学特征影响临床结局,A20 突变与某些桥本甲状腺炎患者的 PTL 发病机制有关。